GlobeNewswire by notified

ObsEva Announces Management Change

Share

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

GENEVA, Switzerland – July29, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced the resignation of Jean-Pierre Gotteland, Chief Scientific Officer and Head of Research & Development, effective September 30, 2022. Dr. Gotteland will step down from the Company's Executive Committee, effective immediately.

“On behalf of the Board of Directors, Executive Committee, and all employees, I would like to thank Jean-Pierre for his contributions to ObsEva over the past seven years. It has been a pleasure to work together and we wish Jean-Pierre all the best in his future endeavors,” said Brian O’Callaghan, CEO of ObsEva.

About ObsEva

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical pipeline with development programs focused on new therapies for the treatment of preterm labor and improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com

Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”, “objective”, “plan”, “potential”, “predict”, “should”, “will”, “would”, or the negative of these and similar expressions, and are based on ObsEva’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties in the outcome and potential impact of the Company’s filing for a court-sanctioned moratorium, including with respect to ObsEva’s agreements with third parties, in ObsEva’s ability to successfully restructure its operations and refocus the Company’s development and commercialization strategy, and to cooperate with Kissei or other third parties on the completion of the linzagolix extension studies, in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, including interactions with the FDA during the New Drug Application process for linzagolix, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:
CEO Administrative Contact
Shauna Dillon
shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Katja Buhrer
katja.buhrer@obseva.com
+1 (917) 969-3438

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

A Step Forward in Human-Robot Collaboration: Han's Robot Opens A New Era of Intelligent Collaborative Robots13.8.2022 02:39:12 CEST | Press release

SHENZHEN, China, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Wang Guangneng, general manager of Han's Robot, said that repetitive, mechanical, and dull work had left us no time to take care of our family and real life. Collaborative robots came into being to solve this issue, allowing robots and workers to work together to improve efficiency. However, this is only the first step. Han’s Robot is developing intelligent collaborative robots that do not require secondary development which users can buy and use according to their needs and costs. Han's Robot is invested and established by Han's Laser, the world's leading industrial laser processing and automation solution provider. It has attracted over 500 top global talents from 25 countries and regions. The core technology R&D team has accumulated more than ten years of industrial experience and mastered the core key technologies of intelligent robots. The product has the advantages of intelligent perception, zero-code programming, zero-sliding wh

Volta Finance Limited: Net Asset Value as at 31 July 202212.8.2022 18:15:00 CEST | Press release

Volta Finance Limited (VTA / VTAS) –July2022 monthly report NOT FOR RELEASE, DISTRIBUTION, OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12August2022 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for June. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY July saw a recovery from the losses faced the previous two months. The fund gained +4.5%, mainly driven by EUR CLO equity holdings (+2,7% contribution in NAV performance). Through asset classes, the monthly performances** were: -2.8% for Bank Balance Sheet transactions, +5% for CLO equity tranches; +2.3% for CLO debt; -5% for Cash Corporate Credit and ABS (together representing 2.3% of NAV). In the footsteps of most markets (July was one of the best months for the High Yield bonds market since years), the loan markets rallied and therefore C

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS12.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-16BondsKOMMUNINVEST I SVERIGE: 2410. SE0010469205. 2024-10-02 KOMMUNINVEST I SVERIGE: 2706, SE0016829048, 2027-06-15 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2022-08-16Bid times10.00-11.00Requested volume (corresponding nominal amount)2410: 200 mln SEK +/-100 mln SEK 2706: 200 mln SEK +/-100 mln SEK Highest permitted bid volume (corresponding nominal amount)2410: 200 mln SEK per bid 2706: 200 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-18Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases of Bonds via Bid Procedure 2020:3. dated 20 November 2020 (see the Riksbank´s web). Stockholm, 2022-08-12 This i

CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS12.8.2022 16:20:00 CEST | Press release

Bid procedure, 2022-08-19BondsSWEDISH GOVERNMENT: 1065. SE0017830730. 2033-11-11 Bid date2022-08-19Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1065: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1065: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2022-08-23Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2022-08-12 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

Mandalay Resources Corporation tillkännager resultatrapporten för andra kvartalet 202212.8.2022 15:44:02 CEST | Pressemelding

TORONTO, Aug. 12, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännager resultatrapporten för kvartalet som slutade den 30 juni 2022. Bolagets sammanfattade och konsoliderade delårsrapporter för kvartalet som slutade den 30 juni 2022, tillsammans med ledningens diskussion och analys (”MD&A”) för motsvarande period, finns tillgängliga under bolagets profil på www.sedar.com och på bolagets webbplats på www.mandalayresources.com. Alla valutor i detta pressmeddelande avser USD om inget annat anges. Höjdpunkter under andra kvartalet 2022: Stärkt balansräkning – en förbättrad nettokassa med 47,9 miljoner USD i likvida medel och 41,5 miljoner USD i totala räntebärande utestående skulder;Konsoliderade kvartalsintäkter på 50,1 miljoner USD;Nettokassaflöde från den löpande verksamheten på 16,1 miljoner USD och fritt kassaflöde på 7,5 miljoner USD1;Konsoliderad kvartalsvis justerad EBITDA1 på 20,3 miljoner USD;Justerat nettoresu